Olaparib for PAH: a Multicenter Clinical Trial (OPTION)

  • End date
    Nov 30, 2023
  • participants needed
  • sponsor
    Laval University
Updated on 9 June 2022
body mass index
serum pregnancy test
pulmonary disease


The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH), to early-phase clinical trials. We, and others, have published strong evidence that DNA damage accounts for disease progression in PAH and showed that PARP1 inhibition can reverse PAH in several animal models1. Interestingly, PARP1 inhibition is also cardioprotective. Olaparib, an orally available PARP1 inhibitor, can reverse cancer growth in animals and humans with a good safety profile, and is now approved for the treatment of ovarian cancer in Canada, Europe and the USA. The time is thus right to translate our findings in human PAH.

The primary objective of this Phase 1B study is to confirm the safety of using olaparib in PAH patients, and precise the sample size of a future Phase 2 trial. In addition to safety, efficacy signals will thus be assessed.


Overall, 20 well-characterized PAH patients that have been stable for >4 months on standard PAH-therapies, as per guidelines will be recruited. The initial Health Canada approval will be obtained. Olaparib will be provided by AstraZeneca Canada, but AZ had no input into the trial design and will not be involved in the conduct of the trial, analysis, interpretation of the results or the final manuscript.

A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of PAH medication.

Given that PAH is a chronic disease and that patients may be at higher risk for drug-related adverse events (e.g. anemia), olaparib will be started at low-dose (100mg BID), then up-titrated weekly by 100mg BID up to 200mg BID (n=5, group 1) or 300mg BID (n=15, group 2) for a total treatment duration (including the up-titration phase) of 24 weeks. Using 100mg and 150mg tablets will allow minimizing the number of tablets taken (e.g. 2 x 150mg tablets BID) or adjusting the dose in case of drug-related adverse events (e.g. 250mg BID using 100mg and 150mg tablets).

Patients will be regularly followed to assess whether side effects are observed and whether olaparib can be up-titrated.

At baseline and week 24, a cardiac catheterization will assess changes in pulmonary hemodynamics and RV function.

An end-of-study visit is planned at week 28 week.

Condition Pulmonary Arterial Hypertension
Treatment olaparib
Clinical Study IdentifierNCT03782818
SponsorLaval University
Last Modified on9 June 2022


Yes No Not Sure

Inclusion Criteria

Informed consent
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses
Type of patient and disease characteristics
PAH of idiopathic/ hereditary/drug or toxin-induced origin or associated with connective tissue diseases
Mean PA pressure ≥25mmHg, PA wedge pressure ≤15mmHg, PVR >480 dyn.s.cm-5 and absence of acute vasoreactivity (we expect PARP1 inhibition will be most effective in patients with significant PA remodelling)
WHO functional class II or III, which is the traditional inclusion criteria in all PAH RCT)
Clinically stable with unchanged vasoactive therapy for ≥4 months; 5) two 6MWD of ≥150m and within ±15% of each other (the latter being used as baseline value)
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below
Haemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x 109/L
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal
Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test
Estimated creatinine clearance =( [(140-age [years]) x weight (kg)] / [serum
creatinine (mg/dL) x 72]) (x F); (where F=0.85 for females and F=1 for males)
Patients must have a life expectancy ≥ 28 weeks
Weight: Body mass index (BMI) within the range 18-40 kg/m2 (inclusive)
Postmenopausal or evidence of non-childbearing status for women of childbearing
Postmenopausal is defined as
potential: negative urine or serum pregnancy test within 28 days of study
treatment and confirmed prior to treatment on day 1
Amenorrheic for 1 year or more following cessation of exogenous hormonal
Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in
the post menopausal range for women under 50
surgical sterilisation (bilateral oophorectomy or hysterectomy)
Male patients must use a condom during treatment and for 3 months after the last
dose of olaparib when having sexual intercourse with a pregnant woman or with a
woman of childbearing potential. Female partners of male patients should also use
a highly effective form of contraception if they are of childbearing potential

Exclusion Criteria

Medical conditions
Systolic blood pressure <90 mmHg
Acute RV failure within the last 3 months
Received any investigational drug within 30 days
Recent cancer (<1yr)
Other types of pulmonary hypertension [130], including pulmonary related to left
Recent bacterial infection (<30 days)
heart diseases (group 2), lung diseases (group 3) or chronic thromboembolic
History of hypertensive crisis
disease (group 4)
Significant restrictive (total lung capacity <60% predicted) or obstructive
(FEV1/FVC<60% after a bronchodilator) lung disease
Cardiopulmonary rehabilitation program planned or started ≤12 weeks prior to Day
Presence of ≥3 risk factors for heart failure with preserved ejection fraction
Prior/concomitant therapy
including: - BMI >30 kg/m2, - Diabetes mellitus, - Hypertension, - Coronary
Any previous treatment with PARP inhibitor, including Olaparib
artery disease
Other organ dysfunction other than RV failure including Childs-Pugh class B-C
liver cirrhosis
Prior/concurrent clinical study experience
Stage ≥1 systemic hypertension, defined as a systolic blood pressure ≥140mmHg or
a diastolic blood pressure ≥90mmHg, or requiring anti-hypertensive therapies
Resting ECG indicating uncontrolled, potentially reversible cardiac conditions
Other exclusions
as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic
arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte
Breast feeding women
disturbances, etc.), or patients with congenital long QT syndrome
Lifestyle restrictions
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features
suggestive of MDS/AML
Patients considered a poor medical risk due to a serious, uncontrolled medical
disorder, non-malignant systemic disease or active, uncontrolled infection
Examples include, but are not limited to, uncontrolled ventricular arrhythmia
recent (within 3 months) myocardial infarction, uncontrolled major seizure
disorder, unstable spinal cord compression, superior vena cava syndrome
extensive interstitial bilateral lung disease on High Resolution Computed
Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining
informed consent
Patients unable to swallow orally administered medication and patients with
gastrointestinal disorders likely to interfere with absorption of the study
Immunocompromised patients, e.g., patients who are known to be serologically
positive for human immunodeficiency virus (HIV)
Patients with known active hepatitis (i.e. Hepatitis B or C). Active hepatitis B
virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result
Patients with a past or resolved HBV infection (defined as the presence of
hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive
for hepatitis C virus (HCV) antibody are eligible only if polymerase chain
reaction is negative for HCV RNA
Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole
telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or
cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or
moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem
fluconazole, verapamil). The required washout period prior to starting olaparib
is 2 weeks
Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin
rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort
) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required
washout period prior to starting olaparib is 5 weeks for enzalutamide or
phenobarbital and 3 weeks for other agents
Major surgery within 2 weeks of starting study treatment and patients must have
recovered from any effects of any major surgery
Previous allogenic bone marrow transplant or double umbilical cord blood
transplantation (dUCBT)
Whole blood transfusions in the last 120 days prior to entry to the study (packed
red blood cells and platelet transfusions are acceptable, for timing refer to
inclusion criteria no.7)
Participation in another clinical study with an investigational product
administered in the last 3 months
Patients with a known hypersensitivity to olaparib or any of the excipients of
the product
Judgment by the investigator that the patient should not participate in the study
if the patient is unlikely to comply with study procedures, restrictions and
Meals and dietary restrictions: It is prohibited to consume grapefruit juice
while on olaparib therapy
Activity: Women of childbearing potential and their partners, who are sexually
active, must agree to the use of TWO highly effective forms of contraception in
combination. This should be started from the signing of the informed consent and
continue throughout the period of taking study treatment and for at least 1 month
after last dose of study drug(s), or they must totally/truly abstain from any
form of sexual intercourse
Male patients must use a condom during treatment and for 3 months after the last dose of
olaparib when having sexual intercourse with a pregnant woman or with a woman of
childbearing potential. Female partners of male patients should also use a highly effective
form of contraception if they are of childbearing potential. Male patients should not
donate sperm throughout the period of taking olaparib and for 3 months following the last
dose of olaparib
For details of acceptable methods of contraception refer to Appendix B Acceptable Birth
Control Methods
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note